Diana V. Kouiavskaia

This paper optimizes a human monoclonal antibody against poliovirus to improve its serum half-life and manufacturability through sequence engineering and experimental evaluation.

This paper develops a mucosal vaccine against EVD68 using an NDV vector and evaluates its immunogenicity in mice, finding robust antibody responses but no protection against infection.

This study shows that imprinted antibody lineages can persist for over 50 years and dominate cross-neutralizing recall responses to poliovirus.

This paper develops a method using viral vectors to encapsidate replicon RNAs for safe anti-enterovirus vaccines, showing similar efficacy to existing vaccines in mice.